Proteome Systems Inks Marketing Deal with DCN
Diagnostic Consulting Network will market and develop Proteome Systems’s PXL diagnostic platform, DiagnostIQ, and biomarker discovery expertise under a memorandum of understanding reached by the two companies late last week.
Financial terms of the deal were not announced.
DCN develops diagnostic tests from prototype stage through the commercialization stage. Under the agreement with Proteome, DCN will promote the company’s test platform under its One Step Solution program to its customers. DCN will also develop prototype diagnostic tests using DiagnostIQ and its third-party customers’ test reagents and antibodies, Proteome said in a statement.
Once feasibility is established, the customers will seek a commercial license directly from Proteome.
Whatman’s Multiplex Protein Chip Receives European Regulatory Approval
Whatman said this week that its Combichip multiplex protein biochip has received CE registration as an in vitro diagnostic and will be available to reference labs as a CE-marked IVD kit.
The product, indicated for autoimmune diseases, won the agency’s approval around three months later than its most recent prediction, and around eight months later than it had originally expected it to become approved.
The Combichip requires a single, low-volume serum sample to generate results for 14 different analytes. It also reduces analysis time to two or three hours, Whatman said.
The assay system, developed in partnership with Privates Institut fur Immunologie und Molekulargenetik, currently identifies antibodies associated with approximately 10 different autoimmune diseases, including systemic and neonatal lupus and systemic sclerosis.
Matritech Told It Does Not Meet Listing Requirements
Matritech will submit a plan to American Stock Exchange prior to Oct. 23 after receiving a letter from the exchange saying it does not meet certain requirements to continue being listed.
In a letter received by Matritech on Sept. 21, Amex told the company it was not in compliance with certain continued listing standards including shareholder equity less than $2 million and net losses or losses from continuing operations in two of its last three most recent fiscal years; shareholder equity of less than $4 million and net losses or losses from continued operations for three of its last four fiscal years, and shareholder equity of less than $6 million and net losses or losses from operations in five of its most recent fiscal years.
Amex said Matritech has until Oct. 23 to submit a plan to bring the company back in compliance with listing standards. If Amex does not approve the plan, it can initiate delisting proceedings.
Teva, Protalix Agree to Develop Two Biopharmaceuticals
Teva Pharmaceuticals will use Protalix Biotherapeutics’ plant cell culture platform to develop two proteins for biopharmaceutical purposes under a collaboration announced this week.
The two companies will collaborate on research and development of the proteins. Teva will be granted an exclusive license from Protalix to commercialize the products in return for royalty and milestone payments. Protalix will retain certain manufacturing rights.
Further financial details of the agreement were not disclosed.
Axela, Abnova Collaborate on dotLab System
Axela Biosensors and Abnova will co-develop reagents and biomarker panels for Abxela’s dotLab System, the companies announced this week. The dotLab System is used to analyze and validate protein biomarkers.
Financial terms of the deal were not disclosed.
Under the agreement, Abnova will optimize a series of monoclonal antibodies for the quantitation of specific serum protein biomarkers for use with the dotLab system, the companies said. Researchers will then be able to mix the monoclonal antibodies with their own reagents to create custom panels for multiplexed protein detection.
JPT Gives Millipore Distribution Rights For Enzyme Products, Services
Millipore received worldwide, non-exclusive rights to distribute JPT Peptide Technologies’ line of enzyme profiling products and services under an agreement announced this week by the two companies.
The products and services covered under the agreement target enzymes such as kinases, phosphatases, and proteases. It includes JPT’s line of Enzyme Substrate sets and microarrays containing peptides with annotated phosphorylation/cleavage sites to study enzymatic activities and substrate specificities.
New High-End Waters Instruments at ImperialCollegeLondon
Waters announced this week it is expanding its research collaboration with Imperial College of London by equipping the Waters Laboratory of Molecular Spectroscopy at the college with the Waters Acquity UPLC system, the Q-TOF Premier, and the GCT Premier mass spectrometers.
The announcement was made as the college unveiled a new NMR facility incorporating the mass spec-based Waters Laboratory. The new collaboration and facility will allow researchers to research “fundamental medicinal-biology problems. It is hoped that the work done will provide the tools necessary to make significant steps toward the goal of personalized medicine,” the company said in a statement.
Multispan, Molecular Devices to Promote Each Others Tools, Services
Multispan will promote Molecular Devices FLIPR Calcium 4 Assay Kits to its partners and customers under a co-marketing campaign announced this week.
The two companies recently completed an evaluation of the assay kit for GPCR screening. Multispan will promote FLIPR in conjunction with Molecular Devices’ promotion of Multispan’s GPCR compound profiling service and stable cell-line assays to its customers, the companies said in a statement.
Financial terms of the agreement were not disclosed.
Board OKs Pressure BioSciences Stock Repurchase
Pressure BioSciences board has approved a stock repurchase of $500,000 of its outstanding common shares in the common market or in privately negotiated transactions, the company announced this week. The timing and amount of any repurchase will depend on factors including market and business conditions. The repurchases can be commenced or suspended at any time without prior notice or further announcement.
The company announced also that it purchased 106,600 shares of Kyowa Medex Company at $2.88 per share. Kyowa is the Japanese distributor of Pressure’s legacy business Boston Biomedica.
Pressure holds 13 US and five foreign patents for applications of its pressure cycling technology, including applications for proteomic sample preparation.
Protagen Opens US Facility…
Protagen announced this week it has opened an office in Chester, NJ, its first office overseas. Protagen is based in Dortmund, Germany.
Howard Jacobson will be US Protagen’s CEO while Rick Garretson will be the US account manager.
…While Biosite Opens New European HQ
Biosite has moved its European headquarters to Morges, Switzerland, the company announced this week. The former headquarters for its European operations was in Bruc, France.
In a statement, Gary King, vice president of Biosite’s international operations, said growth of the company’s presence in Europe “requires a strategically located facility to support our business strategy, particularly in the areas of marketing, clinical, and customer support.”